CSL Limited (OTCMKTS:CSLLY – Get Free Report) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 20,000 shares, an increase of 189.9% from the February 13th total of 6,900 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 216,000 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Upgrades and Downgrades
Separately, The Goldman Sachs Group upgraded CSL to a “strong-buy” rating in a research note on Thursday, January 16th.
Read Our Latest Analysis on CSLLY
CSL Stock Performance
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Stories
- Five stocks we like better than CSL
- Find and Profitably Trade Stocks at 52-Week Lows
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.